BRIEF-Neurobo Pharmaceuticals Completes Enrollment Of The Sad Part 1 Of Its Phase 1 Clinical Trial Evaluating Da-1726

Reuters
13 Aug 2024

Aug 13 (Reuters) - Neurobo Pharmaceuticals Inc :

* NEUROBO PHARMACEUTICALS COMPLETES ENROLLMENT OF THE SAD PART 1 OF ITS PHASE 1 CLINICAL TRIAL EVALUATING DA-1726 FOR THE TREATMENT OF OBESITY

* TOP LINE DATA FROM SAD PART 1 EXPECTED Q3 2024

* TOP LINE DATA READOUT FROM MAD PART 2 EXPECTED IN Q1 2025

Source text for Eikon: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10